Synta's (SNTA) Ganetespib Could See Extra Exclusivity Following FDA Meeting - Roth

November 5, 2014 11:40 AM EST
Get Alerts SNTA Hot Sheet
Price: $0.34 --0%

Rating Summary:
    4 Buy, 4 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 38 | Down: 18 | New: 7
Trade Now! 
Join SI Premium – FREE

Roth Capital maintains Synta Pharma (Nasdaq: SNTA) with a Buy rating and price target of $27 following news that the Company has been invited by the U.S. Food and Drug Administration (FDA) to participate in a meeting of the Oncologic Drugs Advisory Committee’s (ODAC) Pediatric Subcommittee on December 11, 2014.

Analyst Joseph Pantginis commented, We are encouraged by the FDA's invitation and by the potential for ganetespib in pediatric malignancies. We believe ganetespib has broad potential in various tumor types and patient populations. With the new CEO in place, we believe the company has the experience and relationship-focus that will be key in driving SNTA forward, including exploring partnering potential.

On tomorrow's quarterly call, we expect to get initial views on the refining of the company's strategy, including the clarity on the path toward commercialization and the financial considerations for all strategic options the company is considering. A more comprehensive vision is expected to be elucidated at the beginning of 2015, but the number one priority at SNTA remains the execution of the GALAXY-2 study. At last update in August 2014, enrollment was on track to meet data readout expectations, which include two anticipated interim analyses in 2H15 and a final survival analysis in 1H16. We are optimistic about this study based on positive randomized Phase II GALAXY-1 data.

For an analyst ratings summary and ratings history on Synta Pharma. click here. For more ratings news on Synta Pharma. click here.

Synta Pharma. closed at $2.95 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Roth Capital